Evaluation of Normal Tissue Toxicities in Head and Neck Cancer Patients Receiving Intensity Modulated Radiotherapy (IMRT)
- Assess salivary function in patients with advanced head and neck cancer treated with
intensity-modulated radiotherapy (IMRT) by measuring stimulated saliva production at 6
and 12 months after completion of therapy.
- Compare salivary function in these patients to salivary function in historical
- Assess auditory, swallow, and voice function and quality of life of these patients
before and after IMRT or chemoradiotherapy.
- Advance experience with IMRT/tomotherapy and improve field design for irradiating head
and neck cancer in an effort to reduce radiation dose and minimize effects on
surrounding normal tissue.
OUTLINE: This is a prospective study.
Patients undergo standard of care high-dose intensity-modulated radiotherapy (IMRT) to the
head and neck.
Patients undergo baseline and post-treatment testing of auditory, salivary, swallow, and
voice function as well as quality of life evaluation.
Patients are evaluated for radiation-induced toxicities at 1, 6, and 12 months after
completion of IMRT.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Stimulated saliva production at 6 months after completion of intensity-modulated radiotherapy (IMRT)
Paul M. Harari, MD
University of Wisconsin, Madison
United States: Federal Government